(Press-News.org) The Department of Energy’s (DOE) Isotope Program, within the Office of Science, will supply a U.S. based company with accelerator produced actinium-225 (Ac-225) in support of an upcoming U.S. clinical trial for cancer therapy for the first time. This is a significant milestone in the advancement of radiopharmaceutical development and cancer therapy because it opens a potential new pipeline for this lifesaving isotope.
"We are proud to enable U.S. based companies to push past the boundaries on how we combat cancer in this country," said Christopher Landers, Director of the Office of Isotope R&D and Production. "This collaboration exemplifies the purpose of our mission to ensure that critical isotopes are readily available to meet domestic needs across all aspects of society, including medical therapies."
The clinical trial is scheduled to begin in summer 2025 and will be the first to rely on accelerator-produced Ac-225 for human patient care. Ac-225 is a radioisotope in short supply because of the current complicated production process. The Isotope Program has established a scalable production method to fill this need using the particle accelerators at DOE's Brookhaven National Laboratory and Los Alamos National Laboratory. For many years, researchers have used the accelerator-produced Ac-225 in developing potential cancer treatment options and in animal studies for safety and efficacy. Now, the accelerator-produced Ac-225 will be explored for clinical use.
The Isotope Program produces critical radioactive and stable isotopes in short supply for the nation and is one of a few or only global producers for these novel isotopes. Isotopes are high-priority commodities of strategic importance and are essential in medical diagnosis and treatment, industrial applications in oil and gas, national security, quantum information systems, space exploration and communications, discovery science and various other applications. Isotopes directly enable emerging technology, and contribute to the economic, technical, and scientific strength of the United States.
END
Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summer
National laboratories’ accelerator-produced Ac-225 to be used in an FDA-approved targeted cancer therapy clinical trial for the first time
2025-06-30
ELSE PRESS RELEASES FROM THIS DATE:
Tens of thousands of heart attacks and strokes could be avoided each year if cholesterol-lowering drugs were used according to guidelines
2025-06-30
A new study led by Johns Hopkins researchers has identified a significant gap between the number of U.S. patients for whom cholesterol-lowering drugs such as statins are recommended and the actual number of patients who take them.
Coronary artery disease remains a leading cause of death in the U.S. and globally, despite the development of statins and other cholesterol-lowering medications in recent decades. Many adults who should be taking these drugs to lower their low-density-lipoprotein (LDL) levels are not—even though these drugs are considered safe and there is a large body of evidence supporting their effectiveness. In their new study, the researchers sought ...
Leading cancer and metabolic disease expert Michael Karin joins Sanford Burnham Prebys
2025-06-30
Michael Karin, PhD, has long been fascinated by what happens when inflammation—ideally a short-term burst of biological activity to promote healing or fight infection—turns chronic and potentially deadly.
He joined Sanford Burnham Prebys on June 30, 2025, where he will continue investigating how chronic inflammation can promote tumor formation. Karin also will serve as director of the new Center for Metabolic and Liver Diseases.
“Michael is a key leader in the molecular mechanisms that underlie metabolism, inflammation and cancer, and his recruitment to our institute is transformational,” said David A. Brenner, MD, president ...
Low-intensity brain stimulation may restore neuron health in Alzheimer's disease
2025-06-30
Alzheimer’s disease (AD) is a debilitating neurodegenerative condition that affects a significant proportion of older people worldwide. Synapses are points of communication between neural cells that are malleable to change based on our experiences. By adding, removing, strengthening, or weakening synaptic contacts, our brain encodes new events or forgets previous ones. In AD, synaptic plasticity, the brain’s ability to regulate the strength of synaptic connections between neurons, is significantly disrupted. This worsens over time, reducing cognitive and memory functions leading to reduced quality of life. To date, there is no effective ...
Four-day school week may not be best for students, review finds
2025-06-30
A new University of Oregon review of 11 studies found little evidence that the four-day school week benefits student academic performance, attendance, behavior or graduation rates.
The HEDCO Institute for Evidence-Based Educational Practice at the UO conducted the systematic review, a rigorous analysis of the highest-quality research available on the four-day school week in the United States.
“Districts often turn to four-day school weeks to address budget and staffing pressures, but the evidence ...
Using music to explore the dynamics of emotions
2025-06-30
How does the human brain track emotions and support transitions between these emotions? In a new eNeuro paper, Matthew Sachs and colleagues, from Colombia University, used music and an advanced approach for assessing brain activity to shed light on the context dependence and fluctuating nature of emotions.
The researchers collaborated with composers to create songs that evoked different emotions at separate time points. They then assessed the brain activity of study participants as they listened to these songs. Sachs ...
How the brain supports social processing as people age
2025-06-30
Because aging weakens cognitive skills, older people can struggle to read difficult social cues. A brain region involved in attention and arousal—the locus coeruleus (LC)—helps with complex tasks, and its connections to the cortex may adapt as humans age to support cognition. To shed more light on this, Maryam Ziaei, from the Norwegian University of Science and Technology, and colleagues explored whether the LC and its cortical pathways change over time to help process faces that are difficult to read.
In their new JNeurosci paper, the researchers imaged the brains of young (21 to 29 years old) and old (67 to 75 years old) adults as they looked at faces. Older adults ...
Túngara frog tadpoles that grew up in the city developed faster but ended up being smaller
2025-06-30
With 8.2 billion people in the world, cities are constantly expanding, rapidly altering the environment. Animals that undergo complete metamorphosis, such as frogs, may face bigger challenges as they try to survive in new and changing conditions, because their young stages, the eggs and tadpoles, are more vulnerable.
Scientists at the Smithsonian Tropical Research Institute in Panama (STRI) compared the development of tadpoles of Túngara frogs (Engystomops pustulosus) in urban and forest conditions. Túngara frogs, whose mating calls sound like they’ve come straight out of a video game, lay their eggs in foam nests inside puddles. The eggs become tadpoles and, ...
Where there’s fire, there’s smoke
2025-06-30
Earlier this year, wildfires in southern California killed 30 people, destroyed more than 18,000 homes and burned more than 57,000 acres. The fires were a stark reminders of the threat of worsening climate change, and the increased likelihood of future devastating fires. With these fires comes smoke, which has long-term health effects for the people exposed to it – whether they are close to the source, or many miles away.
A Harvard atmospheric modeling team has created an online platform that could help communities identify areas in need of controlled burns ...
UCLA researchers uncover key mechanism of brain repair in vascular dementia, revealing promising therapeutic target
2025-06-30
A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia and demonstrated that targeting this process with a repurposed drug can promote brain repair and functional recovery in mice.
Published in Cell, the research combines laboratory and human data to pinpoint a critical signaling pathway that could lead to the first effective treatment for this understudied form of dementia.
Vascular dementia is the second leading cause of dementia. This disease co-occurs with Alzheimer’s disease in the leading cause of dementia, termed “mixed dementia.” There is no drug therapy that ...
Why Human empathy still matters in the age of AI
2025-06-30
A new study finds that people value empathy more when they believe it comes from a human—even if the actual response was generated by AI. Across nine studies involving over 6,000 participants, the research reveals that human-attributed responses are perceived as more supportive, more emotionally resonant, and more caring than identical AI-generated responses.
A new international study led by Prof Anat Perry from the Hebrew University of Jerusalem and her PhD student – Matan Rubin, in collaboration with Prof. Amit Goldenberg researchers from Harvard University and Prof. Desmond C. Ong from the University of Texas, finds that people place greater emotional value on empathy ...
LAST 30 PRESS RELEASES:
ASU researchers to lead AAAS panel on water insecurity in the United States
ASU professor Anne Stone to present at AAAS Conference in Phoenix on ancient origins of modern disease
Proposals for exploring viruses and skin as the next experimental quantum frontiers share US$30,000 science award
ASU researchers showcase scalable tech solutions for older adults living alone with cognitive decline at AAAS 2026
Scientists identify smooth regional trends in fruit fly survival strategies
Antipathy toward snakes? Your parents likely talked you into that at an early age
Sylvester Cancer Tip Sheet for Feb. 2026
Online exposure to medical misinformation concentrated among older adults
Telehealth improves access to genetic services for adult survivors of childhood cancers
Outdated mortality benchmarks risk missing early signs of famine and delay recognizing mass starvation
Newly discovered bacterium converts carbon dioxide into chemicals using electricity
Flipping and reversing mini-proteins could improve disease treatment
Scientists reveal major hidden source of atmospheric nitrogen pollution in fragile lake basin
Biochar emerges as a powerful tool for soil carbon neutrality and climate mitigation
Tiny cell messengers show big promise for safer protein and gene delivery
AMS releases statement regarding the decision to rescind EPA’s 2009 Endangerment Finding
Parents’ alcohol and drug use influences their children’s consumption, research shows
Modular assembly of chiral nitrogen-bridged rings achieved by palladium-catalyzed diastereoselective and enantioselective cascade cyclization reactions
Promoting civic engagement
AMS Science Preview: Hurricane slowdown, school snow days
Deforestation in the Amazon raises the surface temperature by 3 °C during the dry season
Model more accurately maps the impact of frost on corn crops
How did humans develop sharp vision? Lab-grown retinas show likely answer
Sour grapes? Taste, experience of sour foods depends on individual consumer
At AAAS, professor Krystal Tsosie argues the future of science must be Indigenous-led
From the lab to the living room: Decoding Parkinson’s patients movements in the real world
Research advances in porous materials, as highlighted in the 2025 Nobel Prize in Chemistry
Sally C. Morton, executive vice president of ASU Knowledge Enterprise, presents a bold and practical framework for moving research from discovery to real-world impact
Biochemical parameters in patients with diabetic nephropathy versus individuals with diabetes alone, non-diabetic nephropathy, and healthy controls
Muscular strength and mortality in women ages 63 to 99
[Press-News.org] Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summerNational laboratories’ accelerator-produced Ac-225 to be used in an FDA-approved targeted cancer therapy clinical trial for the first time